Status:
UNKNOWN
Pulmonary Hypertension Screening for Rheumatology Patients (SOPHIE)
Lead Sponsor:
The University of Hong Kong
Conditions:
Connective Tissue Diseases
Systemic Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
Pulmonary arterial hypertension (PAH) is a serious and often fatal complication of connective tissue diseases including systemic sclerosis and systemic lupus erythematosus. It has been reported primar...
Detailed Description
Objectives: 1. To detect pulmonary hypertension amongst patients with connective tissue diseases through systematic screening 2. To understand the prevalence of pulmonary hypertension in Chinese pati...
Eligibility Criteria
Inclusion
- Patientw with either (1) systemic lupus erythematosus, (2) systemic sclerosis, or (3) other connective tissue diseases at risk of pulmonary hypertension
- Voluntarily agrees to participate by providing written informed consent
- Age ≥ 18 at enrolment
Exclusion
- \- Refuse to participate the study
Key Trial Info
Start Date :
August 3 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
1800 Patients enrolled
Trial Details
Trial ID
NCT03446339
Start Date
August 3 2017
End Date
December 1 2023
Last Update
August 3 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Hong Kong
Hong Kong, China